Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma

BACKGROUND: Olaratumab, a fully human monoclonal antibody, selectively binds to human platelet‐derived growth factor receptor alpha and blocks ligand binding. This study assessed the effect of olaratumab on the pharmacokinetics (PK) of doxorubicin and the safety of olaratumab alone and in combinatio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Villalobos, Victor M., Mo, Gary, Agulnik, Mark, Pollack, Seth M., Rushing, Daniel A., Singh, Arun, Van Tine, Brian A., McNaughton, Rhian, Decker, Rodney L., Zhang, Wei, Shahir, Ashwin, Cronier, Damien M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6997100/
https://ncbi.nlm.nih.gov/pubmed/31821732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2728
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados